All In Biotech

Drug Trial Radar · NCT07446153

A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects

An Open Label, Multicenter Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

282

Planned (sponsor's estimate)

Start

Mar 19, 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open, multicenter, Phase I/II clinical trial, divided into three stages: dose escalation, dose expansion and efficacy expansion.

Conditions

  • Solid Tumor

Interventions

  • HRS-8364 TabletDrug

    HRS-8364 tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Dose-Limiting Toxicity (DLT)Time frame: Post-dose at Day 1 to Day 21.
  2. The Maximum Tolerated Dose (MTD)Time frame: Post-dose at Day 1 to the end of treatment visit, about 1 year.
  3. Recommended dosage for Phase II (RP2D)Time frame: Post-dose at Day 1 to the end of treatment visit, about 1 year.
  4. Incidence and severity of adverse events (AEs)Time frame: From signing the informed consent form to safety follow-up completed, about 1 year.
  5. Objective Response Rate (ORR)Time frame: From the first administration to the end of treatment visit, about 1 year.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Sixth Affiliated Hospital, Sun-Yat-Sen University

    Guangzhou, Guangdong, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.